Patients with IBS experience recurrent abdominal pain associated with altered bowel movements. and resulting immune responses, and dysregulation of gut-brain nerve pathways collectively contribute to IBS. Alterations in colonic motor function, changes in gut microbiota, increased intestinal permeability IBS is a common, chronic disorder of gut–brain interaction, with a multifactorial Introduction

Keywords: abdominal pain, TRPV1, sodium absorption, intestinal permeability

Findings: Abdominal pain is experienced through activation and signaling of nociceptive dorsal root ganglia that innervate the gut. These sensory afferent neurons may become hypersensitized through signaling of transient receptor potential cation channel subfamily V member 1 (TRPV1), resulting in reduced action potential thresholds. TRPV1 signaling is also a key component of the proinflammatory cascade involving mast cell responses to macromolecule exposure following permeation through the intestinal epithelium. Indirect evidence of this pathway is supported by observations of higher pain in association with increased intestinal permeability in patients with IBS. Tenapanor reduces intestinal sodium absorption, leading to increased water retention in the intestinal lumen, thereby improving gastrointestinal motility. In animal models of visceral hypersensitivity, tenapanor normalized visceromotor responses and normalized TRPV1-mediated nociceptive signaling.

Conclusion: By improving gastrointestinal motility, decreasing intestinal permeability and inflammation, and normalizing nociception through decreased TRPV1 signaling, tenapanor may reduce visceral hypersensitivity, leading to less abdominal pain in patients with IBS-C. Therapies that have demonstrated effects on visceral hypersensitivity may be the future direction for meaningful abdominal pain relief for patients with IBS-C.

Keywords: IBS-C, NHE3, abdominal pain, TRPV1, sodium absorption, intestinal permeability

Introduction

Irritable bowel syndrome (IBS) is a common, chronic disorder of gut–brain interaction, with a multifactorial pathophysiology. Alterations in colonic motor function, changes in gut microbiota, increased intestinal permeability and resulting immune responses, and dysregulation of gut-brain nerve pathways collectively contribute to IBS. Patients with IBS experience recurrent abdominal pain associated with altered bowel movements. According to the Rome IV criteria, IBS diagnosis requires ≥1 weekly episode of abdominal pain for ≥3 months related to ≥2 of the following: change in stool form, change in stool frequency, and/or defecation. Based on these criteria, an estimated 4% of the world’s population has IBS.

IBS is classified into four subtypes based on stool consistency; the most common are IBS with diarrhea and IBS with constipation (IBS-C) and occur in 31.5% and 29.3% of patients with IBS according to the Rome IV criteria, respectively.
patients with IBS-C, >25% of bowel movements are of Bristol Stool Form Scale types 1 (nut-like lumps) or 2 (sausage-shaped and lumpy), with <25% being of Bristol Stool Form Scale types 6 ( mushy) or 7 (pure liquid).2

Although not associated with an increased mortality risk,5 IBS negatively impacts health-related quality of life,6,7 as well as activities of daily living.8,9 Among patients with IBS-C, pain is often regarded as the most troublesome abdominal symptom.10 Indeed, a survey of patients with IBS-C in the United States revealed that abdominal pain was the underlying cause of 91.1% of disease-related emergency department visits or hospitalizations.10 Abdominal pain was an independent predictor of US outpatient and emergency department visits among 434 patients with disorders of gut–brain interactions, including IBS, functional constipation, and functional diarrhea.11 Patients with IBS-C also experience additional abdominal symptoms, including bloating, discomfort, cramping, and fullness.12,13 Strategies to alleviate the symptoms of IBS-C include dietary interventions (eg, fiber supplementation, avoidance of specific foods), over-the-counter laxatives, and prescription medications.3,14,15 Neither dietary fiber nor laxatives have been demonstrated to alleviate abdominal pain.3,15,16 While treatment satisfaction rates vary depending on regimen, overall, 35–64% of patients with IBS-C report being dissatisfied with existing over-the-counter and/or prescription medications.17,18 Lack of improvement in abdominal pain is a common reason for treatment discontinuation, as noted by 29–42% of patients in the CONTOR study.18 Thus, patients with IBS-C remain in need of more effective treatments that target the underlying cause of abdominal pain.

Mechanistic Underpinnings of Abdominal Pain

Abdominal pain in patients with IBS is due in part to perturbations in nociception, a phenomenon referred to as visceral hypersensitivity.19 Increased intestinal permeability and low-grade intestinal inflammation have been hypothesized to act as triggers for visceral hypersensitivity.20,21 Visceral pain scores following colorectal distension were shown to be significantly higher in patients with IBS with increased intestinal permeability (defined as a lactulose-to-mannitol ratio ≥0.07) than in patients with IBS with normal intestinal permeability (lactulose-to-mannitol ratio <0.07).22 Supernatants derived from colonic biopsies of patients with IBS have been demonstrated to increase the paracellular permeability of cultured colonic epithelial cells, and the degree of supernatant-induced permeability has been correlated with the severity of patient-reported abdominal pain.23 A compromised epithelial barrier creates an environment permissive to the movement of macromolecules, mast cells, and mast cell mediators from the intestinal lumen across the epithelium. These macromolecules have the potential to cause inflammation that can trigger visceral hypersensitivity.20,21

The prevalence of visceral hypersensitivity in patients with IBS varies widely from 8% to 90%.24–26 Visceral hypersensitivity can be assessed clinically by colorectal balloon distension.25 Patients with IBS have lower thresholds for the pain and discomfort associated with this procedure compared with healthy volunteers.27–31 While there is evidence that altered central nervous system processing of visceral input may contribute to visceral hypersensitivity, other studies strongly support the importance of peripheral mechanisms of visceral pain in IBS.32,33

Transient receptor potential cation channel subfamily V member 1 (TRPV1) is expressed in nociceptive sensory neurons of the gastrointestinal tract34,35 and plays a role in sensing stimuli such as heat and the presence of capsaicin.36 In mouse models, knockout of the Trpv1 gene significantly reduced the ability of mice to sense (ie, neuronal impairment) and respond to colorectal distension.37 In rat models of colonic hypersensitivity, TRPV1 has been demonstrated to maintain visceral hypersensitivity, and treatment with a TRPV1 antagonist has been shown to blunt visceromotor responses following colorectal distension.38,39 Collectively, these data from animal models implicate TRPV1 as a mediator of visceral hypersensitivity in humans. The number of TRPV1-positive nerve fibers has been shown to be elevated in colonic biopsies of patients with IBS relative to healthy controls.34,35 Both TRPV1 transcription levels and immunoreactivity to TRPV1 protein have been shown to correlate positively with abdominal pain scores in patients with IBS.34,40 Additional clinical evidence in support of the relationship between TRPV1 and visceral hypersensitivity stems from studies in patients with quiescent inflammatory bowel disease whose symptoms do and do not satisfy the Rome criteria for IBS. The number of TRPV1-positive neuronal fibers was 5-fold higher in colorectal biopsies from patients with inflammatory bowel disease who reported ongoing abdominal pain compared with those who did not.41 Furthermore, in multivariate analyses,
TRPV1 positivity was the only covariate found to be significantly associated with the abdominal pain score in these patients.\textsuperscript{41} The association of TRPV1 with visceral hypersensitivity in clinical evidence thus further supports the role of TRPV1 as a mediator of visceral hypersensitivity in patients with IBS.

In other experiments, visceral hypersensitivity was demonstrated to be “transferrable” from patients with IBS to animals, suggesting that soluble factors could also be at play. For example, inoculating germ-free rats with the fecal microbiota from patients with IBS-C with visceral hypersensitivity led to a significant increase in abdominal contractions upon colorectal distension (ie, increased visceral sensitivity) compared with rats inoculated with the fecal microbiota from healthy volunteers.\textsuperscript{42} Exposure of guinea pig submucosal neurons to colon supernatants from patients with IBS-C induced increased neuronal activation, as measured by spike discharge.\textsuperscript{43} Additionally, enteric and dorsal root ganglia (DRG) neuronal responses were more pronounced when colon supernatants were derived from patients with IBS with visceral hypersensitivity than from those with normosensitivity.\textsuperscript{24} IBS-C and IBS-D–derived colonic biopsy supernatants can also stimulate human enteric neuron cultures.\textsuperscript{44}

During intestinal inflammation, the number of activated mast cells, as well as the number of mast cells in close proximity (within 5–10 μm) to colonic neurons, was significantly increased in patients with IBS compared with healthy controls as revealed by examination of the colonic mucosa.\textsuperscript{45,46} The physiological relevance of mast cell infiltration to increased visceral hypersensitivity in patients with IBS is underscored by the positive correlation between the number of mast cells proximal to colonic nerves and the severity of abdominal pain or discomfort.\textsuperscript{45} This influx of mast cells is accompanied by significant increases in locally released pro-nociceptive mediators such as histamine, tryptase, prostaglandin E2, prostaglandin D2.\textsuperscript{45–47} Indeed, each of these mediators has been shown to sensitize TRPV1, and levels of these mediators are elevated in the colonic mucosa of IBS patients compared with healthy controls.\textsuperscript{47} Furthermore, targeting these mast cell mediators has been shown to suppress the ability of mucosal supernatant derived from patients with IBS to activate TRPV1-expressing DRG isolates from rats.\textsuperscript{46} In addition to histamine, mast cells also secrete the cytokine interleukin 6 (IL-6).\textsuperscript{48} Serum and plasma IL-6 levels have been shown to be significantly elevated in patients with IBS relative to healthy controls.\textsuperscript{50} Further, IL-6 can also activate submucosal and myenteric neurons.\textsuperscript{50,51} In a rat model of IBS, blockade of IL-6 signaling decreased visceral hypersensitivity, as demonstrated by an increase in the pain threshold for colorectal distension.\textsuperscript{50}

### Mechanism of Action of Tenapanor

Tenapanor is a minimally absorbed first-in-class inhibitor of sodium/hydrogen exchanger isoform 3 (NHE3),\textsuperscript{52–54} an antiporter expressed on the apical membrane of epithelial cells lining the small intestine and proximal colon.\textsuperscript{55} NHE3 is the predominant NHE isoform involved in the transepithelial absorption of sodium from the gut.\textsuperscript{56} Tenapanor-mediated inhibition of NHE3 leads to reduced sodium absorption and subsequent retention of water in the intestinal lumen (Figure 1).\textsuperscript{52–54,57} Water retention, in turn, accelerates intestinal transit, resulting in softer stool consistency and improved gastrointestinal motility.

Dose-dependent increases in stool sodium content and luminal fluid retention were reported in rats given single oral doses of tenapanor, and repeated dosing over 4 days resulted in sustained increases in stool sodium that returned to baseline when tenapanor was discontinued.\textsuperscript{54} In healthy volunteers, twice-daily (BID) doses of tenapanor 15–60 mg increased the amount of stool sodium retention by 20–50 mmol/day;\textsuperscript{53,54} absorption of 50 mmol sodium is equivalent to 2.8 g of table salt.\textsuperscript{53} In healthy volunteers, administration of tenapanor led to demonstrable increases in stool frequency and stool weight relative to placebo.\textsuperscript{53} Importantly, the sodium retention effects of tenapanor are limited to the gut, with no impact on serum/plasma sodium levels.\textsuperscript{53,58}

As discussed above, the presence of abdominal pain is a hallmark of IBS,\textsuperscript{2} and visceral hypersensitivity may have pathophysiologic relevance to these abdominal pain experiences.\textsuperscript{19} The mechanistic effects of tenapanor on abdominal pain have been evaluated in a rat model of acetic acid–induced colonic hypersensitivity.\textsuperscript{59} In this model, oral tenapanor 0.5 mg/kg BID significantly reduced visceromotor responses to colorectal distension relative to vehicle. Interestingly, the visceromotor responses observed in tenapanor-treated, acetic acid–sensitized rats with colonic visceral hypersensitivity were comparable to those recorded in naïve rats (ie, those not treated with acetic acid). Additionally, in single-cell patch-clamp experiments in colon-specific DRG obtained from acetic acid–sensitized rats, tenapanor reversed the DRG
hyperexcitability following exposure to the TRPV1 agonist capsaicin, which suggests that tenapanor can normalize TRPV1-mediated nociceptive signaling (Figure 1). Interestingly, studies with human colonic epithelial monolayers have shown that tenapanor reduces intestinal cell permeability to macromolecules. Given the relationship between intestinal permeability and visceral hypersensitivity noted above, it is likely that improvement in barrier function by tenapanor is in part responsible for improvement in visceral hypersensitivity.

**Clinical Effects of Tenapanor**

The ability of tenapanor to inhibit sodium absorption and normalize enteric sensory neuron excitability and intestinal permeability translates to clinical improvements in global IBS-C symptoms, including amelioration of abdominal pain and increases in bowel movement frequency in patients with IBS-C. In the Phase 3 T3MPO-1 (NCT02621892) and T3MPO-2 (NCT02686138) studies, which were of 12 and 26 weeks’ duration, respectively, the primary endpoint was the proportion of patients with IBS-C who experienced both a ≥30% reduction in mean weekly worst abdominal pain score (abdominal pain response) and an increase of ≥1 complete spontaneous bowel movement relative to baseline in the same week for ≥6 of the first 12 weeks of treatment. Significantly, more patients randomized to receive tenapanor 50 mg BID met the primary endpoint compared with those who received placebo in T3MPO-1 (27.0% vs 18.7%; P=0.020) and T3MPO-2 (36.5% vs 23.7%; P<0.001). In secondary analyses, proportionally more patients in the tenapanor group than in the placebo group had a clinically meaningful abdominal pain response for ≥6 of the first 12 weeks of treatment (T3MPO-1, 44.0% vs 33.1%; P=0.008; T3MPO-2, 49.8% vs 38.3%; P=0.004), ≥9 of the first 12 weeks of treatment (T3MPO-1, 30.3% vs 19.4%; P=0.003; T3MPO-2, 35.8% vs 26.7%; P=0.015), and ≥13 of 26 weeks of treatment (T3MPO-2, 50.2% vs 40.0%; P=0.013) (Table 1; Figure 2).

![Figure 1](https://doi.org/10.2147/CEG.S454526) Reprinted from King AJ, Chang L, Li Q, et al. NHE3 inhibitor tenapanor maintains intestinal barrier function, decreases visceral hypersensitivity, and attenuates TRPV1 signaling in colonic sensory neurons. Am J Physiol Gastrointest Liver Physiol. 2024. Online ahead of print.

**Abbreviations:** IBS-C, irritable bowel syndrome with constipation; NHE3, sodium/hydrogen exchanger isoform 3; TRPV1, transient receptor potential cation channel subfamily V member 1.
score for ≥9 of the first 12 weeks of treatment including ≥3 weeks during weeks 8–12 (T3MPO-1, 29.3% vs 19.4%; \(P=0.006\); T3MPO-2, 34.8% vs 26.7%; \(P=0.028\)) (Table 1; Figure 2). At each week of the 12-week T3MPO-1 and 26-week T3MPO-2 trials, tenapanor 50 mg BID led to statistically significant reductions in mean abdominal pain score compared with placebo. Additionally, among 186 patients in the T3MPO-2 trial who received tenapanor for the 26-week treatment period and reported weekly average abdominal pain score at baseline and at week 26, the percentage reporting moderate-to-severe abdominal pain (weekly average pain score of 3–10 on a 0–10 scale) decreased from 100% prior to treatment to 38% after 26 weeks of treatment with tenapanor, with 31% reporting none (weekly average pain score of <1) (Unpublished data). Tenapanor also alleviated other abdominal symptoms experienced by patients with IBS-C such as bloating, discomfort, cramping, and fullness.63

Consistent with tenapanor’s action to increase water retention in the intestinal lumen and improve gastrointestinal motility, most treatment-emergent adverse events in the phase 3 studies were gastrointestinal in nature. The most common adverse event reported among tenapanor-treated patients was diarrhea (14.6% in T3MPO-1, 16.0% in T3MPO-2, and 11.1% in T3MPO-3) (Table 2). Diarrhea often occurred within the first 3 weeks of treatment. Most episodes were transient, resolving within 1 week and were of mild or moderate severity.61,62,64 In the clinical trial setting, diarrhea was associated with a low rate (<10%) of treatment discontinuation. Based on the efficacy and safety data derived from T3MPO-1 and –2, tenapanor was approved by the US Food and Drug Administration in 2019 for the treatment of adults with IBS-C.65 In 2022, the American Gastroenterological Association endorsed the use of tenapanor for the treatment of IBS-C, based on the certainty of scientific evidence in its most recent clinical practice guideline update at the time of this writing.14

### Table 1 Summary of Tenapanor Efficacy Demonstrated in the T3MPO-1 and T3MPO-2 Studies

<table>
<thead>
<tr>
<th></th>
<th>T3MPO-1</th>
<th>T3MPO-2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Placebo (n=299)</td>
<td>Tenapanor (n=307)</td>
</tr>
<tr>
<td>≥6 of 12 weeks of treatment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reduction in average weekly worst abdominal pain of ≥30% from BL and increase of ≥1 CSBM per week from BL (Primary endpoint)</td>
<td>18.7%</td>
<td>27.0%</td>
</tr>
<tr>
<td></td>
<td>(P=0.020)</td>
<td>(P&lt;0.001)</td>
</tr>
<tr>
<td>Clinically meaningful abdominal pain response(^a)</td>
<td>33.1%</td>
<td>44.0%</td>
</tr>
<tr>
<td></td>
<td>(P=0.008)</td>
<td>(P=0.004)</td>
</tr>
<tr>
<td>≥9 of 12 weeks of treatment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinically meaningful abdominal pain response(^a)</td>
<td>19.4%</td>
<td>30.3%</td>
</tr>
<tr>
<td></td>
<td>(P=0.003)</td>
<td>(P=0.015)</td>
</tr>
<tr>
<td>Durable abdominal pain response(^b)</td>
<td>19.4%</td>
<td>29.3%</td>
</tr>
<tr>
<td></td>
<td>(P=0.006)</td>
<td>(P=0.028)</td>
</tr>
<tr>
<td>≥13 of 26 weeks of treatment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinically meaningful abdominal pain response(^a)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes: BL values for the treatment period were the average of values from weeks 1 and 2 of the screening period. \(^a\)Reduction in average weekly worst abdominal pain of ≥30% from BL. \(^b\)Reduction of ≥30% in mean weekly abdominal pain score for ≥9 of the first 12 weeks of treatment, including ≥3 weeks during weeks 8–12.

Abbreviations: BL, baseline; CSBM, complete spontaneous bowel movement.
Conclusion

Abdominal pain is perhaps the most troublesome abdominal symptom experienced by IBS-C patients, significantly impacting healthcare utilization and quality of life. The pathophysiology of abdominal pain is believed to be multifactorial, resulting from visceral hypersensitivity, which may be exacerbated by increased intestinal permeability and associated inflammatory responses. Patients with IBS-C also experience other abdominal symptoms, such as bloating, discomfort, cramping, and fullness. Tenapanor alleviates abdominal symptoms and constipation in patients with IBS-C through a unique and innovative mechanism of action, acting locally to inhibit NHE3, while travelling through the gut lumen until it is excreted rather than being absorbed. The clinical effects of tenapanor on abdominal pain are demonstrated in Figures 2A and 2B.
pain may be mediated through reducing visceral hypersensitivity by normalizing TRPV1 activation as well as restoring intestinal barrier function, based on results from nonclinical studies.59,60 The use of tenapanor in patients with IBS-C was endorsed by the American Gastroenterological Association based on its efficacy in increasing complete spontaneous bowel movement frequency and improving abdominal pain, while being safe and tolerable with transient, mild-to-moderate diarrhea being the most common adverse event. Visceral hypersensitivity contributes to the underlying etiology of abdominal pain in IBS-C, and treatments targeting the underlying visceral hypersensitivity could bring meaningful relief to patients with IBS-C.

Abbreviations
BID, twice daily; DRG, dorsal root ganglia; IBS, irritable bowel syndrome; IBS-C, irritable bowel syndrome with constipation; IL-6, interleukin 6; NHE, sodium/hydrogen exchanger; NHE3, sodium/hydrogen exchanger isoform 3; RR, relative risk; TRPV1, transient receptor potential cation channel subfamily V member 1.

Acknowledgments
Medical writing support for the development of this manuscript, under the direction of the authors, was provided by Ashfield MedComms (US), an Inizio company, and was funded by Ardelyx, Inc.

Author Contributions
All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Funding
Medical writing and editing support for this review article was funded by Ardelyx, Inc.

Disclosure
Prashant Singh reports no conflicts of interest in this work. Gregory S. Sayuk consulted for AbbVie/Ironwood, Ardelyx, Inc., Regeneron/Sanofi, and Salix and served on speakers bureaus for and received honoraria from AbbVie/Ironwood, Ardelyx, Inc., GI Health Foundation, Regeneron/Sanofi, Rome Foundation, and Salix. David P. Rosenbaum, Kenji Kozuka and Susan Edelstein are employees of Ardelyx, Inc. Lin Chang has served on a scientific advisory board for Ardelyx, Inc. Lin Chang also reports personal fees/grants from Atmo, Arena, Bausch Health, Ironwood, and AbbVie; stock options from Trellus Health, Food Marble, and ModifyHealth, outside the submitted work. In addition, Lin Chang has a patent Ref.: 2018-578-2 (Serial number 63/499,017) issued. These authors report no other conflicts of interest in this work.

### Table 2 Summary of Tenapanor Safety Demonstrated in the T3MPO-1 and T3MPO-2 Studies

<table>
<thead>
<tr>
<th></th>
<th>T3MPO-1 Placebo (n=301)</th>
<th>T3MPO-1 Tenapanor (n=309)</th>
<th>T3MPO-2 Placebo (n=300)</th>
<th>T3MPO-2 Tenapanor (n=293)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TRAEs</td>
<td>18 (6.0)</td>
<td>57 (18.4)</td>
<td>28 (9.3)</td>
<td>64 (21.8)</td>
</tr>
<tr>
<td>Serious AEs</td>
<td>0</td>
<td>4 (1.3)</td>
<td>6 (2.0)</td>
<td>4 (1.4)</td>
</tr>
<tr>
<td>AEs leading to drug discontinuation</td>
<td>2 (0.7)</td>
<td>23 (7.4)</td>
<td>3 (1.0)</td>
<td>23 (7.3)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>5 (1.7)</td>
<td>45 (14.6)</td>
<td>11 (3.7)</td>
<td>47 (16.0)</td>
</tr>
<tr>
<td>Treatment-related diarrhea</td>
<td>2 (0.7)</td>
<td>41 (13.3)</td>
<td>8 (2.7)</td>
<td>44 (15.0)</td>
</tr>
<tr>
<td>Diarrhea leading to discontinuation</td>
<td>2 (0.7)</td>
<td>20 (6.5)</td>
<td>2 (0.7)</td>
<td>19 (6.5)</td>
</tr>
</tbody>
</table>

**Abbreviations:** AE, adverse event. TRAE, treatment-related adverse event.
References


Dovepress


